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Abstract 
Rationale: Diabetes mellitus (DM) is recognized as a common comorbid condition for 
tuberculosis (TB). Those with comorbid conditions are more likely to develop active TB, to have 
trouble with treatment, and to have more severe symptoms.  
Objective: To measure the prevalence and distribution of latent tuberculosis infection (LTBI) and 
DM control in the United State and test their association when measured by tuberculin skin test 
(TST) or QuantiFERON®-TB Gold In-Tube blood test (QFT-GIT) and by HbA1c, respectively. 
Literature Review: One-third of the world population is infected with TB. Ten percent of TB 
cases worldwide are linked to diabetes mellitus. Studies have found that the risk of TB increases 
with the presence of DM.  
Methods: This is a cross-sectional, secondary analysis study of the 2011-2012 National Health 
and Nutrition Examination Survey. The study population included 4,222 participants. Frequency 
and proportions of each variable were calculated. Then calculations of the frequency and 
conditional distribution of LTBI for the predictors were made. The chi-square test of association 
was used to test relationship between LTBI and DM control. Finally, unadjusted and adjusted 
odds of LTBI were calculated using binary and multiple logistic regressions, respectively.  
Main Results: The chi-square test of association found that LTBI and DM control are not 
independent. The unadjusted logistic regression showed significantly increased odds of having 
LTBI for those with HbA1c levels corresponding prediabetes and diabetes compared to those 
with normal HbA1c levels, which the adjusted logistic regression did not.  
Conclusion: This study found that LTBI and DM control were associated. There was increased 
likelihood of having LTBI with poorer diabetes mellitus control, however, the increased odds 
disappeared when accounting for covariates.                                                 Word Count:   272 
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Introduction  
Identification and management of comorbid conditions are becoming essential elements for 
successful tuberculosis (TB) control programs, especially in regions with high incidence of TB. 
Health organizations around the world are recognizing a rapidly increasing trend of TB cases 
concomitant with communicable or noncommunicable diseases. These comorbidities are 
significantly affecting the incidence and prevalence rates of TB (Narasimhan, Wood, MacIntyre 
and Mathai, 2013). Those with comorbid conditions are more likely to develop active TB  from 
exposure to Mycobacterium tuberculosis, to have reactivation of the disease from latent 
tuberculosis infection (LTBI), to have an increased likelihood of treatment relapse and to express 
more severe symptoms when active with TB disease (Narasimhan et al., 2013). Even regions of 
the world with low prevalence of TB are beginnning to notice the effect of comorbid burdens, 
especially in their most at- risk populations.  
 
Diabetes mellitus (DM) has become recognized as the most common comorbid condition for TB. 
Health organizations in regions endemic for TB have deemed it more common than even the 
more severe and widely known co-infection, HIV/AIDS (Garcia-Elorriaga & Del Rey-Pineda, 
2014). The trend of this connection between DM and TB is found in both low and high incidence 
countries. The United States is a low incidence country. Typically, the TB health burden in low 
incidence countries rests on the most vulnerable portions of the population. These groups are 
more likely to be burdened due to recent exposure because of migration from higher incidence 
countries or because of the effects of health disparities. In any case, transmission is low in non-
endemic countries, so most TB cases arise due to reactivation of latent tuberculosis infection 
(LTBI) from past exposure.  
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Specific Aims: 
The purpose of this study is to assess the relationship between latent tuberculosis infection 
(LTBI) and diabetes mellitus (DM) control in the United States. This study aims to determine if 
there is a significant statistical association between the nationwide prevalence trends and also to 
review the influence of confounders, effect modifiers, and covariates on that relationship. In 
developed, high-income countries like the United States, LTBI is most prevalent in groups. This 
study will also highlight some of the most at-risk subpopulations that are more likely to be 
affected by health disparities or are most likely to have had previous exposure thus, are most 
vulnerable to developing concomitant DM/TB.  
 
Objectives: 
1. To test the association of the DM control measured by hemoglobin A1C levels to LTBI 
identified by tuberculin skin test measurements and QuantiFERON blood test results. 
2. To assess the prevalence and distribution of LTBI and DM control in the US population 
in the year span of 2011-2012.  
 
Literature Review 
The following is a review of the literature outlining important concepts for understanding the 
nature of the relationship between tuberculosis and diabetes mellitus. The references cited 
include published scholarly articles, organizational reports, public health organization and 
governmental fact sheets and websites. Searches for these sources were performed using Google 
search engine, Google Scholar, Endnote, and PubMed Central databases. The works cited only 
includes articles and documents published in English. Keywords and phrases used in searches 
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include: latent tuberculosis infection, tuberculosis and diabetes mellitus, diabetes mellitus 
control, glycemic control, bidirectional screening, co-epidemic of communicable and 
noncommunicable diseases, tuberculosis in the United States, diabetes epidemic, risk factors for 
diabetes, risk factors for tuberculosis, national and global prevalence, comorbidity, WHO, CDC, 
developed country, developing country, epidemiology, DR- & MDR-TB, race and ethnicity and 
tuberculosis, socioeconomic status and tuberculosis, tuberculosis in low incidence country, risk 
factors, U.S. and global statistics, and etc. Additional sources were found by subsequent review 
of the bibliography of previously found works cited. The review begins with a summary of 
current health burden of tuberculosis and latent tuberculosis infection highlighting key 
characteristics of the disease in the 21st century. Then it goes on to describe the global epidemic 
of diabetes mellitus and explores aspects of its convergence with tuberculosis.  
 
Global epidemiology of tuberculosis (TB): 
The CDC reports that one-third of the world’s population is infected with TB, second only to 
HIVAIDS as an infectious disease killer worldwide (“Data and Statistics,” 2014; “Tuberculosis,” 
2016). Some 9.6 million persons became sick with TB resulting in 1.5 million TB-related deaths 
worldwide in 2014 (“Data and Statistics,” 2015). At least 58% of these cases were in South-East 
Asia and Western Pacific regions (“Global Tuberculosis Report,” 2015). According to the WHO, 
95% of TB-related deaths occur in low- and middle- income countries (“Tuberculosis,” 2016). 
The Millennium Development Goal target of halting and reversing TB has been met throughout 
the world, and incidence has fallen 1.5% per year since 2000 leading to a current rate 18% lower 
than the incidence level in 2000 (“Tuberculosis,” 2016). The new Sustainable Development Goal 
is to end the TB epidemic by 2030 (“Tuberculosis,” 2016). Currently the WHO also reports that 
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the death rate due to TB has dropped 47% between 1990 and 2015 with an estimated 43 million 
lives saved by diagnosis and treatment by 2000 and 2014 (“Tuberculosis,” 2016).  The WHO 
established a global reporting system in 1995, which has since reported 78 million TB cases with 
66 million of them successfully treated (“Global Tuberculosis Report,” 2015). 
 
Active Tuberculosis in the United States: 
Reports for 2014 indicated an overall incidence rate of 3.0 cases per 100,000 persons in the 
United States between 2013 and 2015 (Salinas, Mindra, Haddad, Pratt, Price, & Langer, 2016). 
According to the CDC, 9,421 TB cases were reported in the United States in 2014 (with a rate of 
2.96 cases per 100,000 persons), and other sources indicate a preliminary count of 9,563 TB 
cases reported for 2015 (“Data and Statistics,” 2015; Kanabus, 2016). Similar to the global trend, 
the rate of tuberculosis in the United States is steadily declining. In 2014, the number of TB 
cases reported decreased 1.5% and the case rate decreased 2.2% from the number reported in 
2013 (Scott, Kirking, Jefferies, & Price, 2015). Though the number of TB-related deaths was 555 
in 2013, which was an 8%, increase from the previous year, the annually reported number of 
fatalities has declined 67% since 1992 (Scott et al., 2015). Despite the stable nature of TB in the 
United States, the goal of elimination set in 1989 (recommitted in 1999) has not been met, and 
the decline rate has experienced the smallest decrease in decades (Scott et al., 2015). In fact, 
most recent reports affirm a leveling or stalling of the decline or reduction of most measures for 
TB, but experts are striving to develop effective methods of TB detection and treatment (Salinas 
et al., 2016). 
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Latent M. tuberculosis infection (LTBI): 
LTBI refers to a “state of persistent immune response to stimulation by Mycobacterium 
tuberculosis antigens without evidence of clinically manifested active TB” (“Latent 
Tuberculosis” 2014). The primary differences between latent and active tuberculosis infection is 
that the former is without symptoms, non-infectious, sputum smear test results are negative, has 
normal chest X-ray findings and the treatment focus is to prevent progression to active disease 
(Hartman-Adams, Clark, & Juckett, 2014). LTBI is a major factor hindering complete 
elimination of tuberculosis, even in low-risk countries like the United States. Most cases of TB 
arise from reactivation of LTBI instead of new exposures; this is particularly evident in high-risk 
groups or vulnerable subpopulations (Scott et al., 2015). The WHO estimates that one in three 
people in the world has an LTBI and are at risk of TB reactivation (“Latent Tuberculosis,” 2014) 
This includes the estimate for the U.S. of 11 million persons with LTBI (“Latent Tuberculosis 
Infection, 2014; “Tuberculosis & Diabetes,” 2015). It is estimated that the lifetime risk of TB 
reactivation is 5-10% with 50% of this risk being in the first five years of initial infection, and 
the risk is higher when predisposing risk factors are present (“Latent Tuberculosis,” 2014; 
Hartman-Adams et al., 2014). The CDC equates this reactivation probability to 550,000 to 
1,100,000 people developing TB in their lifetime without appropriate treatment for LTBI 
(“Latent Tuberculosis Infection” 2014). 
 
Progression from TB to LTBI: Screening practices and risk factors: 
Risk of progression to disease from infection with Mycobacterium tuberculosis is one of the 
focuses of most TB control strategies in use today. The risk is mitigated by monitoring exposure 
to exogenous risk factors, screening, and treatment (Narasimhan et al., 2013).  Identification and 
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treatment of LTBI is the key to TB elimination especially in persons with coexisting risk factors 
(“Targeted Tuberculin Testing,” 2000; “Latent Tuberculosis,” 2014; “Targeted Tuberculin 
Testing,” 2000). Strong screening practices have significantly helped keep the incidence and 
prevalence of TB down in all regions of the world because a decision to test for TB is typically a 
decision to provide follow-up treatment (“Targeted Tuberculin Testing,” 2000). There are 
multiple screening methods available to identify LTBI; the choice is made based on the exposure 
situation and type of clinical presentation. In most cases, proactive screening is done using tests 
like the Tuberculin Skin Test or IGRAs (Interferon-Gamma Release Assays) (i.e. 
QuantiFERON® Gold in Test Tube blood test) (“Latent Tuberculosis,” 2014). These tests are 
widely used in non-endemic regions like the United States. In endemic areas with high 
incidences of active TB disease these tests are not favorable. They cannot differentiate between 
immune responses due to viable (and infectious) microorganisms and healed/treated infections, 
nor do they accurately predict which infected cases will actually progress to active TB (“Latent 
Tuberculosis,” 2014). Also, preventive measures like the BCG vaccine, widely used in these 
regions, can produce confounding immune response results; this is especially true with 
tuberculin skin tests (TST) (“Targeted Tuberculin Testing,” 2000; Belknap, Wall, & Reves, 
2008). Sweeping, routine screening is avoided bases on recommendations made by public health 
experts. They state that the application of routine testing outside of high-risk groups produces 
“more false-positive results” and “creates needless anxiety” (Hartman-Adams et al., 2014). 
Primary care providers are the front line towards elimination of the disease responsible for 
finding high-risk groups and promoting active screening efforts in endemic and non-endemic 
regions alike (“Latent Tuberculosis Infection,” 2014). Such efforts have worked well in countries 
like the United States to reduce incidence of active TB to the current low rates (“Targeted 
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Tuberculin Testing,” 2000; Narasimhan et al., 2013). The “central pillar of the TB control in the 
U.S.” is the targeted testing and treatment of high-risk population for LBTI as they serve as a 
reservoir of LTBI and the greatest challenge for eliminating active TB from the U.S. population 
(Manuco, Diffenderfer, Ghassemieh, Horn, & Kao, 2016). This practice is called “targeted 
tuberculin testing” and current recommendations encourage a TB control strategy consisting of a 
combination of this and “preventive therapy” which is the treatment of LTBI before progression 
to disease (“Targeted Tuberculin Testing,” 2000).   
 
Several risk factors contribute to LTBI and TB disease at both individual and population levels 
(Narasimhan et al., 2013). One article arranges these risk factors into three categories: factors 
related to the index case, factors related to the individual, and finally demographic factors 
(Narasimhan et al., 2013). The first category includes factors that affect risk of infection (e.g. 
bacillary load at exposure or proximity to an infectious case); the second category relates to the 
factors characteristic to the at-risk individual; and the final group accounts for population 
characteristics (Narasimhan et al., 2013). These categories would be considered first by exposure 
situation then by population characteristics and finally by individual characteristics. Membership 
of certain subgroups will affect the influence of these categories. For example, in the United 
States, recent immigrants and foreign-born persons from high incidence countries, individuals 
living or working in institutional settings, the homeless, or patients and healthcare workers are at 
special risk (Narasimhan et al., 2013; Cain, Haley, Armstrong, Garman, Wells, Iademarco, 
Castro, & Laserson, 2006; Hartman-Adams et al., 2014). For a more specific example, there are 
factors like differences in the rate of active TB by ethnicity in the U.S. For example, the cases 
per 100,000 persons for is 18.9 Asians, 12.3 for Native Hawaiians/other Pacific Islanders, 6.3 for 
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American Indians/Alaska Natives, 5.8 for Blacks, 5.3 for Hispanics and 0.8 for Whites 
(Hartman-Adams et al., 2014). Sources find that the incidence and prevalence of active TB for 
these ethnic groups in the U.S. corresponds somewhat with the global distribution of those 
measures in high-incidence areas like most of the countries in African, Asia, Eastern Europe, 
Central American, and South America (Hartman-Adams et al., 2014). Additional individual level 
risk factors include “illicit drug use”, “age younger than five”, being underweight, abuse of 
alcohol, “immunosuppressive disease (e.g. AIDS, HIV, leukemia, lymphoma, chronic kidney 
disease requiring dialysis)”, immunosuppressive therapy, lung parenchyma abnormalities in 
smokers and patients with lung cancer, being of a medically underserved or low-income groups, 
“abnormalities on chest X-rays displaying health fibrotic changes from past M.tuberculosis 
infection”, and diabetes mellitus especially in cases with poor glycemic control (Hartman-Adams 
et al., 2014). Another source describes the risk of progression as a “two-stage process governed 
by both exogenous and endogenous risk factors. Exogenous factors play a fundamental role in 
accentuating the progression from exposure to infection (Garcia-Elorriaga & Del Rey-Pineda, 
2014). It also goes on to describe endogenous factors similar to the three previously described 
plus two more: socioeconomic and behavioral factors and health system issues (Garcia-Elorriaga 
& Del Rey-Pineda”, 2014).  
 
Growing Global Burden of Diabetes Mellitus: 
Diabetes mellitus (DM) is a disease where blood glucose levels are above normal because the 
body is either not making or cannot make use of insulin to prevent build-up of glucose in the 
blood and to help distribute it to the cells of the body (“Basics About Diabetes,” 2015). DM is 
one of the few chronic diseases listed as a risk factor for TB. It is also a rapidly growing chronic 
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epidemic worldwide. According to the WHO, the prevalence of diabetes has “quadrupled since 
1980 to 422 million (8.5%) in adults today” (“World Health Day,” 2016). Currently, 29.1 million 
people have diabetes (21.0 million diagnosed and 8.1 million undiagnosed) in the U.S.; this 
accounts for 9.3% of the total population (“National Diabetes Statistics Report,” 2014). Diabetes 
is the seventh leading cause of death in the United States, responsible for serious health 
complications such as heart disease, blindness, kidney failure, and lower-extremity amputations 
(“Basics about Diabetes,” 2015). DM is typically diagnosed with the start of symptoms (i.e. 
frequent urination, excessive thirst, unexplained weight loss, extreme hunger, sudden vision 
changes, tingling or numbness in hands or feet, very dry skin, more infections than usual, and 
sores that are slow to heal) rather than regular screening (“Basics About Diabetes,” 2015). The 
lifetime risk of progression from LTBI to active TB with DM is 30% compared to the 5-10% 
estimated previously without it (Hartman-Adams et al., 2014; “Latent Tuberculosis,” 2014).  
 
Five percent of diagnosed cases are Type 1 diabetic (insulin-dependent), 90-95% of all 
diagnosed cases are Type 2 diabetic (non-insulin-dependent), and 1%-5% of all diagnosed cases 
of diabetes result from other illnesses, genetic syndromes, surgery, drugs, malnutrition, and 
infections; other cases arise due to gestational diabetes which occurs only in pregnant women 
(“Basics About Diabetes,” 2015). Common risk factors for Type 2 diabetes include a family 
history of DM, prior history of gestational diabetes, impaired glucose tolerance, older age, 
obesity, physical inactivity, and race/ethnicity, while the risks for Type 1 are less defined 
(“Basics About Diabetes,” 2015). Type 1 and Type 2 DM are both treated by healthy eating, 
physical activity, and insulin injections, but Type 2 DM patients also require “oral medication, 
insulin, or both to control their blood glucose” (“Basics About Diabetes,” 2015). Another DM 
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related classification of growing concern and relevant to this study is called prediabetes. Pre-
diabetes is when the blood glucose level is higher than the normal range, but not high enough to 
be diagnosed with diabetes (“National Diabetes Statistics Report,” 2015). Prediabetics are at a 
high risk of developing Type 2 diabetes, though not all cases progress to diabetes. Even so, 
experts state that without intervention the progress from prediabetes to diabetes would happen in 
10 years or less (“National Diabetes Statistics Report,” 2015; “Prediabetes,” 2015).  
 
History of the convergence: 
The association between diabetes mellitus and tuberculosis has been observed and reported since 
quite early in medical history. Some sources cite reports made by ancient Greek philosophers 
like Avicenna around 1000 A.D. and texts written by Indian siddhars (saints) sometime in the 
15th century (Restrepo, 2007).  These accounts clearly describe conditions and symptoms that are 
now known to be attributed to concomitant diabetes mellitus and tuberculosis (Niazi & Kalra, 
2012). In the early 20th century, European and American physicians conducted observational 
medical studies observing the serious distress of patients with DM/TB (Restrepo, 2007; 
Oscarsson, 2009; Root, 1934; Dillon, Boucot, Cooper, Meir, & Richardson, 1952; Banyi, 1931). 
These studies occurred before the development of modern synthetic insulin or effective 
mycobacterial drugs meaning these particular associations were observed when either condition 
was not able to be best controlled (Restrepo, 2007; Oscarsson, 2009, Root, 1934; Dillon et al., 
1952; Banyi, 1931). There are even surveys administered before the 1960s, which determined 
that TB was 2-4 times more common in diabetics than in non-diabetics (Restrepo, 2007; 
Oscarsson, 1958; Root, 1934; Dillon et al., 1952; Banyi, 1931). It has been reported as far back 
as the 1930s that patients with DM have a 3 to 4-fold increased risk of developing TB (Garcia-
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Elorriaga & Del Rey-Pineda, 2014; Restrepo, 2007). The studies and surveys highlighted the 
inclusion of juvenile subjects comorbid with insulin dependent (Type 1) diabetes and pulmonary 
tuberculosis in their results, while more recent studies reveal a sort of “rediscovery” of the 
relationship between DM and TB where the connection is being noticed more often in cases with 
Type 2 DM (Jeon & Murray, 2008; Baker et al., 2011). In any case, Type 1 DM still adds a 
stronger risk of contracting TB when present despite the fact that Type 2 DM is more prevalent 
(Niazi & Kara, 2012). 
 
DM as a risk factor for TB:  
The WHO reports that 10% of TB cases around the world are linked to diabetes, and the rapidly 
growing health burden of DM has taken the risk associated with TB from an individual level to a 
population level (“Tuberculosis & Diabetes,” 2011; “Garcia-Elorriaga & Del Rey-Pineda”, 2014; 
Restrepo, 2007). The WHO reports 2-3 times higher risk of TB in diabetics compared to people 
without DM (“Tuberculosis & Diabetes,” 2011). DM is becoming a more common risk factor 
associated with TB (“Garcia-Elorriaga & Del Rey-Pineda”, 2014). Now in endemic regions, the 
WHO recommends rigorous implementation of treatments for people with TB/DM 
(“Tuberculosis & Diabetes,” 2011). The concern is that as the global burden of DM rises the 
efforts to reduce the incidence of TB will be undermined and all regions of the world – endemic 
and non-endemic – will witness an increase in TB cases (Baker et al., 2011; Jeon & Murray, 
2008).  
 
Efforts for TB control are now focused on preventive strategies prompting a shift in research to 
explore evolving risk factors influencing the spread of TB (Niazi & Kalra, 2012). Global and 
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local organizations are proactively collaborating in research and control program development 
resulting in the publication of guidelines like the Collaborative Framework for Care and Control 
of Tuberculosis and Diabetes (“Collaborative Framework,” 2011). The summaries of 
consultation meetings to determine research gaps, update the knowledge base with recent 
discoveries, and provide consolidated recommendations to be disseminated (“Tuberculosis & 
Diabetes,” 2011; Ottmani, Murray, Jeon, Baker, Kapur, Lonnroth, and Harries, 2010). The 
evidence available to support the association between DM and TB is limited according to the 
latest consultation meeting (Ottmani et al., 2010). The identified limitations are that “1) many of 
the studies were health facility-based, with a case-control design; 2) most of the studies were 
carried out in industrialized countries; and 3) none of the studies used the oral glucose tolerance 
test (OGTT) to diagnose DM” (Ottmani et al., 2010). These points address epidemiologic 
requirements for generalization of samples and accuracy of measures. Since these observations 
were made at this particular meeting in 2009, more studies have been performed outside of 
industrialized countries in developing regions in Sub-Saharan Africa, Asia, and South East Asia 
where TB is most prevalent in the world using differenct biomarkers for TB (Jeon & Murray, 
2008; Baker et al., 2011).  
 
Biological elements of the convergence: 
A weak immune system increases the risk of progression from latent infection to active TB 
disease. Thus chronic illnesses like DM with immunosuppressive effects are understandably 
predisposing factors (“Tuberculosis & Diabetes,” 2011).  Actually, without considering 
connections to TB, DM is an independent risk factor for lower respiratory tract infections, and 
diabetics suffer more severe complications due to infections than non-diabetics (Niazi & Kalra, 
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2012). Growing evidence is demonstrating a consistently evolving relationship, and many source 
describe a bi-directional interaction where each disease exacerbates and increases the likelihood 
of adverse outcomes for the other (Niazi & Kalra, 2012). For example, DM increases the risk of 
progression to disease from infection, reactivation of latent infection, death during TB treatment, 
and of relapse after treatment, while concomitant DM/TB is associated with poor glycemic 
control in DM patients mostly due to the stress of the infection on the body (Garcia-Elorriaga & 
Del Rey-Pineda, 2014). It is important to note that it is diabetes, specifically DM control, 
observed as a predisposing factor to TB rather than TB infection leading to DM (Skowronski, 
Zozulinska-Ziotkiewicz, & Barinow-Wojewodzki, 2013). Nonetheless, increased screening for 
both conditions would improve outcomes for patients. Most studies show and experts are urging 
testing for DM, and subsequent efforts to maintain glycemic control to improve the outcome of 
TB treatment in endemic or high risk populations (“Tuberculosis & Diabetes,” 2011; Garcia-
Elorriaga & Del Rey-Pineda, 2014). Public health organizations like the WHO recommend that 
all persons with TB be screened for DM along with screening for TB in DM patients living in 
endemic or high-risk populations (“Tuberculosis & Diabetes,” 2011). Early detection is crucial to 
controlling and reducing severity of both, but a significant portion of people with DM and TB 
are not diagnosed (“Tuberculosis & Diabetes,” 2011).  
 
There are many speculations of the pathogenesis of concomitant DM and TB. The complexity of 
the association lies in determining if DM increases susceptibility to initial TB infection or if it 
only increases the likelihood of progression from latent infection to active disease (Skowronski 
et al., 2013). In either case, diabetes studies in animal models and even human plasma cells 
prove that diabetes “impairs the innate and adaptive immune responses necessary to counter the 
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proliferation of TB” (Jeon & Murray, 2008). There is evidence of a reduced number of 
macrophages and a delayed innate immune response to the presence of infected alveolar 
macrophages in diabetics (Skowronski et al., 2013). Studies also observed that tuberculosis 
specific IFN-у-producing T cells migrated later to lymph nodes and the lungs (Skowronski et al., 
2013). The adaptive immune response begins to express a shift to T helper 2 (Th2) cell bias and 
their cytokines, which correlates with susceptibility to TB unlike Th1 response (Skowronski et 
al, 2013).  The offset of the ratio of Th2 cells to Th1 cells significantly impairs the adaptive 
immune response, because of decreased T (Th1) cell-mediated immune signaling essential for 
control defenses against infections like TB (Jeon & Murray, 2008; Garcia-Elorriaga & Del Rey-
Pineda, 2014). Even with these findings, the exact pathophysiological mechanisms of the effect 
of DM as a predisposing risk factor for TB is unconfirmed, and research continues to explore the 
extent of physiological complications found in concomitant DM/TB cases (Baghaei, Marjani, 
Javanmard, Tabarsi, & Masjedi, 2013).  
 
Epidemiology of the convergence: 
Systematic reviews of cohort studies reveal that DM presents 3 times the risk of developing 
TB, and it increases the risk of death to 6.5-6.7 times (Baker et al., 2011; Jeon & Murray 2008; 
Garcia-Elorriaga & Del Rey-Pineda, 2014). It is evident now that the link between DM and TB is 
most prominent in developing countries where TB is endemic, and there are high incidences of 
TB; for example India, has the largest number of TB cases and about 25% of those patients have 
diabetes (in addition to 24% of patients with prediabetes) (Baghaei et al., 2013; Restrepo et al., 
2006; Dobler, Flack & Marks, 2012; Skowronski et al., 2013). Notably, the risk of TB due to 
DM is smaller at the individual level compared with HIV infection by 113-170 fold, but at the 
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population level, the number of diabetic patients is likely to have an equal or greater effect 
(Skowronski et al., 2013). Even a study conducted in Australia which has a low TB burden, 
demonstrates an association, though a moderate one (RR= 1.48; 95% CI: 1.04-2.10 for Type 2 
DM and RR=2.27; 95% CI: 1.41-3.66 for Type 1 DM) (Skowronski et al. 2013). However, the 
results can vary as seen where a study from the UK demonstrates an overall adjusted DM of 3.8 
(95% CI: 2.3-6.1), while in another from Denmark, after controlling for comorbidities the OR 
was low and not significant (OR= 1.18, 95% CI: 0.96-1.45) (Skowronski et al., 2013).   
 
Almost all of these observational studies show significant interactions in high-risk subgroups in 
non-endemic regions like Australia, the United Kingdom, and the United States (Restrepo et al., 
2006; Dobler et al., 2012; Suwanpimolkul, Grinsdale, Jarisberg, Higashi, Osmond, Hopewell, & 
Kato-Maeda, 2014; Skowronski et al, 2013). One study on a population on the South Texas-
Mexico border found that DM comorbidity with TB is exceeding that of HIV/AIDS (though 
HIV/AIDS is a more potent risk factor) as is becoming a trend observed in many other studies 
(Restrepo et al., 2006). Another study performed on the Texas-Mexico border found that self-
reported DM is the most common risk factor for TB and DM, and is associated with more severe 
and contagious TB (Restrepo et al., 2006). Finally, a study performed in San Francisco found a 
disproportionate association of TB, using LTBI as the measure) and DM among older foreign-
born individuals (Suwanpimolkul et al., 2014). These results justify a current trend of focusing 
on subgroup characteristics in non-endemic regions to keep from missing potential outbreak 
causing issues. Though there is no doubt of the association between DM and TB, there is a lack 
of for more etiological evidence (Ottmani et al., 2010). Also, the nature of the association and 
actual potential impact is ever evolving from a public health perspective.  
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Methods 
Design & Data Collection: 
This is a cross-sectional study assessing the association between DM and LTBI in adults in the 
United States via secondary analysis of the 2-year cycle 2011-2012 National Health and 
Nutrition Examination Survey.  The National Health and Nutrition Examination Survey 
(NHANES) is part of a program of studies used by the National Center for Health Statistics 
(NCHS) to assess the health and nutritional status of adults and children in the U.S (“About the 
National Health,” 2014). The NCHS is a division of the Centers for Disease Control and 
Prevention (CDC) responsible for collecting vital and health statistics (“About the National 
Health,” 2014). The NHANES is a unique program that uses a complex, multistage probability 
design to sample through a combination of examinations, laboratory tests, and questionnaires 
performed in mobile examination centers (MECs) (“Survey Overview,” 2013; “NHANES 2011-
2012 Overview,” 2014). This design also involves oversampling of certain subpopulations to 
allow for more reliable and precise estimates of health status indicators. A survey team consists 
of a physician, medical and health technicians, and dietary and health interviewers (bilingual 
interviewers are also available when necessary), which travels to randomly selected sites 
throughout the country (“Survey Overview,” 2013). The MECs provide a standardized 
environment, equipment, and specimen collection procedures to minimize site-specific errors 
during examinations and laboratory testing. An interviewer using Computer-Assisted Personal 
Interview (CAPI) technology administers questionnaires. Questionnaires on special topics of a 
sensitive nature are completed on Audio Computer-Assisted Self Interview technology (Audio-
CASI) to allow for privacy. Each participant is given a brochure and asked to sign participation 
consent forms collecting and storing their information (“2011-2012 National Health,” 2014; 
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“Survey Overview,” 2013).  Additional information about the NHANES study design and data 
collection process can be found on the CDC website1 (“National Health and Nutrition,” 2016). 
 
Study population: 
The sample selection process was performed in 4 stages: 1) selection of primary sampling units 
(PSUs) which were counties or small groups of adjacent counties, 2) selection of segments 
within PSUs which consisted of a block or group block of a cluster of indeviduals within 
households (“NHANES 2011-2012 Overview,” 2014). In addition to oversampling of Hispanics, 
non-Hispanic Blacks, older adults and low-income Whites/Other2, a change in sample design for 
this survey cycle includes a oversample of Non-Hispanic Asians (“NHANES 2011-2012 
Overciew,” 2014). The sample sizes for each cycle are fied due to operational constraints, so to 
accommodate the increase in sample sizes fro Asian sample sizes for Hispaic persons and non-
low income White/Other are reduced (“NHANES 2011-2012 Overview,” 2014). As a result, the 
sample size for Mexican American Hispanic persons is noticeably lower than previous years. 
Suvey materials were made available in various languages to promore participant interaction and 
facilittate data collection and oversamping. For example, a video shown to participants to explain 
aspects and benefits of particiapting in the NHANES was made available in Mandarin Chinese, 
Koren, Vietnamese, Amharic, French, Haitian Creole, Hindi, and Spanish (“NHANES 2011-
2012 Overview,” 2014). The staff who administered the surveys received cultural competency 
training and were supported by local interpreters and professional medical interpretation phone 
services. The original 2011-2012 NHANES dataset targeted the civilian, noninstitutionalized 
                                                          
1 http://www.cdc.gov/nchs/nhanes/index.htm  
2 Other refers to Non-Hispanic persons reporting races other than black, Asian, or white.  
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popoulation residing in the 50 states and D.C. The initial sample included 13,431 inidividuals of 
all ages from 30 different study locations: of those selected 9,756 completed the interview, and 
9,338 were examined resulting in unweighted responses rates of 72.6% and 69.5% respectively 
(“NHANES 2011-2012 Overview,” 2014; National Health and Nutrition,” 2013”). 
 
The selection process from this study began with 9,756 paricipants from the original dataset. 
Participants weere evaluated to meet the following critereia to confirm inclusion in the study: 1) 
participant in 20 years3 or older and 2) participant is not missing measures for TST induration 
and QFT-G blood test and and HbA1c levels. This resulted in the unweighted study sample 
sample size of 4,222. Figure 1 provides a breakdown of this selection process. 
 
Measures of Interest: 
Outcome Variables 
Latent Tuberculosis Infection is the dependent /response variable of interest identified by a 
positive tuberculin skin test induration measurement (TST) or QuantiFERON®-TB Gold In-
Tube blood test (QFT-GIT). A TST is performed by injecting 0.1 mm of purified protein 
derivative product, acting as a TB antigen, into the inner surface of the forearm (“Tuberculin 
Skin Testing,” 2012). A properly administered injection will produce a skin reaction which is 
measured to determine if a person is infected with Mycobacterium tuberculosis (“Tuberculin 
Skin Testing,” 2012). The skin reaction appears as an elevation of the skin (a wheal or “palpable, 
raised, hardened area or swelling”) which must be read 48 to 72 hours after the injection by 
                                                          
3 Age criteria updated to 20+ years due to the nature of how original data was collected. NHANES survey includes data for 18-
19 years with children & adolescents for most covariates relevant to this study. This separation resulted in a significant amount 
of missing data. 
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measuring the diameter of the indurated area in millimeters (“Tuberculin Skin Testing,” 2012). 
Interpretation of the measurement of induration to determine LTBI status varies by the risk of 
exposure to Mycobacterium tuberculosis and risk of infection once exposed. An induration of 
≥10 millimeters is used to indicate a positive TST and LTBI (Mancuso et al., 2016).   
QuantiFERON®-TB Gold In-Tube test (QFT-GIT) is an FDA-approved blood test for detecting 
TB infection. It was included in the NHANES 2011-2012 cycle as a secondary screening 
administered on the MECs on the same day the participants are skin tested. This test detects Cell 
Mediated Immune (CMI) responses to peptide antigens that simulate mycobacterial proteins 
(“Interferon-Gamma,” 2016). Anyone infected with M. tuberculosis will usually have 
lymphocytes able to recognize mycobacterial antigens; this recognition process generates and 
secretes a cytokine, IFN-у and the basis of this test is the recognition and quantification of IFN-у 
(“Interferon-Gamma,” 2016).  Blood samples were collected via venipuncture into three 
specialized blood collection tubes – a Nil (negative) control tube, a TB Antigen tube, and a 
Mitogen or positive control tube (“Interferon-Gamma,” 2016). The contents of the tube are 
mixed then incubated at 37 ̊ C + 1 ̊ C for 16 to 24 hours; then the plasma collected is measured 
by ELIZA (enzyme-linked immunosorbent assay) for the amount of IFN-у produced in response 
to the peptide antigens present (“Interferon-Gamma,” 2016). International Units (IU) are used to 
report the results of the test samples relative to a standard curve created by testing dilutions of a 
recombinant human IFN-y standard; the test is positive when there is an IFN-y response 
significantly higher than the Nil IFN-y IU/mL value which adjusts for background, non-specific 
IFN-y in the blood samples, and other special immunological traits (“Interferon-Gamma,” 2016). 
A result will be labeled Indeterminate when the blood sample has a low response to the IFN-y 
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positive control, the mitogen stimulated plasma sample, paired with a negative response to the 
TB antigens (“Interferon-Gamma,” 2016).  
Independent Variable 
The independent or explanatory variable of interest is diabetes mellitus (DM) control. The test 
used to identify level of DM control employed in this study measures blood glycohemoglobin 
levels. This test reflects plasma glucose for the previous 120 days and results are reported as 
percentages (“Glycohemoglobin,” 2013). The categories are based on clinical recommendations 
of diagnosis: 6.5% or greater indicates diabetes, 5.7%-6.4% indicates pre-diabetes, and less than 
5.7% is normal (“Glycohemoglobin,” 2013).  Pre-diabetes is where the sugar level is consistently 
higher than normal yet not as high as what is required to be classified as diabetes (“Prediabetes,” 
2015). This category is included in this study because these participants are at most risk of 
developing Type 2 diabetes. This study does not differentiate Type 1 or Type 2 diabetes.  
Covariates 
There were eight covariates included in this study, which were chosen, based on potential as 
confounders4, effect modifiers, and significant cofactors. These included age, race/ethnicity, 
socioeconomic status, body mass index (BMI), country of origin, gender, time of residence in the 
US, and smoking status. The variable for age, AGECAT, was coded by SEQN into three groups: 
20-39, 40-59, and 60+ years using the original NHANES variable DMDEDUC3. This study 
excluded18-19 years because they were included with children/youth measures for other 
covariates in the original NHANES data.  
 
                                                          
4 First potential confounders were chosen based on prior literature, then they were confirmed with further analysis.  
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The original variable for race/ethnicity, RIDRETH3, had six groups: Non- Hispanic White, 
Mexican American, Other Hispanic, Non-Hispanic Black, Non-Hispanic Asian, and Other race 
including multi-racial. Three versions of this variable were tested to compare the effect of race 
with varied stratification: Race2g (White or Other), Race3g (White, Hispanic5  or Other) and 
Race4g (White, Hispanic, Black or Other). Race4g was the final version included in statistical 
analysis. Socioeconomic status was measured in this study using education level. The original 
educational level variable, DMDEDUC2, categorized participants into groups, and the new 
variable, SESEDUC, used 5 of those groups (“Less than 9th grade, 9-12 grade without a 
diploma”, “High school graduate or GED equivalent”, “Some college education or an Associate 
degree”, and “College graduate or above”) as socioeconomic groups. Body Mass Index (BMI) 
was calculated as weight in kilograms divided by height in meters squared rounded to one 
decimal place (“Body Measures,” 2013). Clinically, BMI measures are grouped as Normal (18.5 
to 24.9), overweight (25 to 29.9), underweight (less than 18.5), and obese (30 or more). The 
original NHANES variable, BMXBMI, was continuous, and the variable for this study was 
coded to an ordinal variable BMICAT2. BMICAT2 only included three categories: Normal, 
Overweight, and Obese. Underweight measures were combined with the lowest risk group, 
Normal6. The NHANES does not collect specific details about origin. This characteristic can be 
partially determined with the dataset variable, DMDBORN4, which answers the question “In 
what country were you born?”. The variable, CTRYOB, was created as a dichotomous variable 
(U.S. born or Foreign born) for this study; any participants missing information were grouped 
with the lowest risk category, U.S. born. Length of time in the US is measured in the original 
dataset as DMDYRSUS and was used to code this study’s variable for this indicator, 
                                                          
5 Hispanic combines Mexican American and Other Hispanic categories from original dataset 
6 Underweight produced insignificant values because of extremely small sample size.  
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TIME3INUS. The new variable collapses the groups of DMDYRSUS into three groups: “Less 
than five years”, “5 to 20 years”, and “Greater than 20 years”. The variable smoking status was 
created by combining two NHANES variables, SMQ020 (answer if “Smoked at least 100 
cigarettes in life”) to establish smoking history and SMQ040 (answering the question “Do you 
now smoke cigarettes?”) to determine current smoking status. These were arranged into three 
categories smoking status: “Never,” “Former” and “Current” for this studies smoking status 
variable, SMOKE.7 Finally, the original variable, RIAGENDR, for gender was simply renamed 
GENDER for this study.  
 
Statistical Analysis: 
Statistical analysis software (SAS) Version 9.4 was used for analysis of study population data. 
All applicable datasets were checked for duplicate records and then merged by respondent 
sequence number (SEQN) into one sample dataset. This was a combination of datasets for 
demographics, body measures, examination and laboratory measures from the NHANES 
database (DEMO_G. sas7bdat; BMX_g. sas7bdat, SMQ_g. sas7bdat; TBX_G. sas7dbat; 
GHB_G. sas7bdat). Variables from these datasets were renamed, re-coded, or combined as 
needed for analysis and all irrelevant variables were dropped. For a list of all variables included 
in the new dataset, refer to Table A. for the dataset codebook. Sampling weights was applied to 
all subsequent analysis of data from the 4,222 participants included in this study. This dataset 
was analyzed using Proc Surveyfreq and Proc Surveylogistic SAS procedures to account for the 
weighting, stratification, and clustering used in the survey study design.8  
 
                                                          
7 The proportions for these groups match expected national values: 50%, 25% and 25% respectively.  
8 See the codebook, Table B., for more details. 
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Frequencies and proportions were calculated in univariate analyses to characterize the 
distribution of the LTBI, DM and potential risk factors in the study population. Bivariate analysis 
was used to produce frequencies and proportions to assess the association of DM (HbA1c) and 
covariates (Race, age, gender, etc.) to LTBI (TST and QFT-G). A chi-square goodness of fit test 
was performed for one-way tables for each variable to assess their univariate distributions and a 
chi-square test of association/independence was conducted to examine the relationship of DM 
(HbA1c) and the covariates to LTBI (TST and QFT-G). The relationship between the predictors 
and the response variables (TST and QFT-G) was further assessed by using binary logistic 
regressions to produce unadjusted odds ratios and confidence intervals. Adjusted odds ratios and 
confidence intervals to assess the association between DM and LTBI accounting for significant 
covariates and confounder and effect modifiers were obtained from multivariate logistic 
regressions.  
 
The test for confounding was performed by comparing the crude odds ratio of LTBI for DM 
control with the odds ratio of LTBI for DM stratified by the potential confounder. The test for 
effect modification was performed using SAS by including an interaction variable in the adjusted 
model.  
 
Model selection was performed using SAS to perform an automatic stepwise selection process 
(using a p value= 0.05 for entry and exit) to observe the effect of each covariate on the 
relationship HbA1c with QFT-G and TST in multiple logistic regression. Stratified analysis was 
used to test for confounders and identify potential effect modifiers. Variables and their categories 
were reassessed to best inclusion in model. Additionally, a set of criteria were used to build a 
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model. Variables were included the model if they 1) had a significant association to QFT-G or 
TST or 2) were a confounder and an effect modifier. AIC was used to compare final models to 
determine best option for final analysis. The three candidate models were one chosen based on 
automatic selection process (adding the primary predictor), another chosen based on the criteria 
listed above, and finally, one which included all the predictors of the study.  Adjusted odds ratios 
and confidence intervals obtained from the best model were used to assess the association 
between HbA1c and LTBI accounting for significant covariates, confounders and effect 
modifiers.  
 
The model selection process resulted in three models shown in Table 8 and Table 9. Model-1 
included all of the predictors. Model-2 included only variables deemed significant by stepwise 
auto-selection process based on p-value = 0.05 for entry and exit of the model using SAS. This 
method produced different combinations of covariates for TST and QFT-G, and to remain within 
the scope of this study HbA1c was manually added back into the model. In addition to HbA1c, 
Model-2 for TST included covariates: race/ethnicity, age, country of birth and smoking status. 
Model-2 for QFT-G included covariates: race/ethnicity, age, country of birth, smoking status and 
SES. Model-3 selected variables based on the set of criteria9 described previously in the methods 
section. The rules ensure that each of these predictors was chosen for specific reasons. HbA1c 
was included as the primary predictor. Race/ethnicity and SES were significantly associated with 
LTBI measures as risk factors, and they are considered risk factors and potential confounders for 
DM status. Country of birth and length of time of residence in the U.S. were significantly 
associated with LTBI measures, and they were essential to study of at risk groups. Finally, age, 
                                                          
9 These are listed in the methods section under the covariates description (pg. 25) 
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gender, and smoking status were included in the models as controls and as characterizing 
variables. The Akaike Information Criterion (AIC) was used to measure the quality of the 
models to choose the “best fit” model. Based on this statistic the “best fit” model was Model-1 
for both LTBI measures; followed by Model 3 and the “least fit” Model-2. However, it is 
important to note that the difference between those values was not substantial.  
This protocol was approved as an exempt study by the University of Kentucky Institutional 
Review Board.  
 
 
Results  
Prevalence and distribution of DM and LTBI in study population: 
Table 1a10 presents the prevalence measures. The prevalence of LTBI in this population, when 
measured by TST and QFT-G, were 5% (CI: 3.9% to 6.8%) and 5.6% (CI: 4.5% to 6.6%), 
respectively. In this study sample, 8.5% (CI: 7.3% to 9.7%) were diabetic, 25% (CI: 22.9% to 
27.3%) were prediabetic and 66% (CI: 64.1% to 68.8%) had normal levels of HbA1c. Table 2 
presents values from the χ2 Goodness of Fit test for equal proportions; all of the variables 
included in this study rejected the null hypothesis of equal proportion between the levels (p-value 
< 0.05). 
 
Description of LTBI based on DM status: 
Table 3a presents the conditional probability and distribution of LTBI for DM status and 
covariates. The primary values of interest are those indicating the relationship between DM 
                                                          
10 Table 1b presents the corresponding frequency counts  
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status and LTBI measures. When measured by TST, 6.4% of prediabetics, 8.1% of diabetics and 
4.1% of individuals with normal HbA1c levels were indicated LTBI. Table 4a presents the same 
values when measured by QFT-G: 7.5% of prediabetics, 10% of diabetics and 4.3% of 
individuals with normal HbA1c levels indicated LTBI. These proportions were reviewed to 
check for an association between LTBI and the covariates. Gender, socioeconomic status, the 
length of time of residence in the U.S. and race/ethnicity showed significant association with 
LTBI when measured by TST, while age, gender, socioeconomic status, race/ethnicity and 
country of birth showed significant association with LTBI when measured by QFT-G. The 
corresponding weighted frequency counts are displayed in Table 3b and Table 4b. 
 
Test of Association and Univariate Odds of LTBI for DM status: 
Table 5 presents values from the Rao-Scott χ2 tests of association between LTBI measures, DM 
status, and covariates. DM status, the primary predictor, indicated a significant association with 
LTBI when measured by both tests. The results of the test of association with the covariates 
varied between QFT-G and TST. Race/ethnicity, the length of time of residence in the U.S. and 
country of birth were significantly associated with LTBI measured by TST, while gender, 
smoking status and body mass index were not. Race/ethnicity, length of time of residence in the 
U.S., country of birth, and gender were significantly associated with LTBI measured by QFT-G, 
while smoking status and body mass index were not.  
 
Table 6 presents the unadjusted odds ratio of LTBI obtained using binary logistic regressions. 
Diabetics had twice the odds of LTBI than those with normal HbA1c levels (OR=2.1; CI: 1.27 to 
3.5), and prediabetics had one and half times the odds of LTBI than those with normal HbA1c 
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levels when measure by TST (OR=1.6; CI: 1.001 to 2.52). Table 7 presents the unadjusted odds 
ratios of LTBI for DM status when measured by QFT-G. Diabetics had two and a half times the 
odds of LTBI than those with normal HbA1c levels (OR=2.5; CI: 1.4 to 4.4), and prediabetics 
had almost twice the odds of LTBI than those with normal HbA1c levels (OR=1.8; CI: 1.4 to 
2.4).   
 
 
Multivariate Odds of LTBI for study population: 
Table 8 and Table 9 also present the adjusted odds ratios of LTBI for DM status and the 
covariates measured by TST and QFT-G, respectively. Models-1 as the “best fit” model was 
used in multiple logistic regressions to calculate the odds of LTBI for DM status. The adjusted 
odds of LTBI, when measured with TST in diabetics, decreased two-fold and was no longer 
significant after controlling for other covariates (OR=1.12; CI: 0.59 to 2.12). The adjusted odds 
of LTBI in prediabetics also decreased and was no longer significant (OR=1.22; CI: .71 to 2.08). 
Also, the odds of LTBI in prediabetics became slightly higher than the odds of LTBI in diabetics. 
The adjusted odds of LTBI when measured with QTF-G also decreased for prediabetics and 
diabetics and were no longer significant (OR=1.28; CI: 0.86 to 1.92 and OR=1.34; CI: 0.62 to 
2.89, respectively).  
 
Testing for confounding and effect modification identified SES as a positive confounder for 
diabetics and Race4g as having a slightly significant interaction with DM status. The 
confounding effect of SES was addressed by including it in the regression analyses DM and 
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LTBI. Effect modification of Race4g at a few of its levels was addressed by analyzing the 
association between DM and LTBI for each strata of the variable 
 
Discussion  
Evaluation of the study 
This study tested for a relationship between LTBI and DM and attempted to determine if DM 
status influenced the impact of LTBI at the population level. This study provided estimates of the 
prevalence of LTBI and DM in the United States in the year span of 2011-2012. A test for 
association confirmed that DM and LTBI were significantly associated and that the probability 
of having LTBI was likely to be different depending on DM status.  
 
The prevalence of LTBI in the study population was quite low, as would be expected of a sample 
from a low-incidence country like the United States. Only about 5 - 5.6% of the total population 
indicated LTBI. This corresponded to 9.2 - 10 million people of a total population of 182.9 
million people. Another study which also used 2011-2012 NHANES cycle had similar results; 
they estimated that 4.4 - 4.8% of their total population indicated LTBI with a corresponding with 
12.4 - 13.6 million people (Mancuso et al., 2016). Overall, their study had lower estimates 
compared to ours. One reason for the different results could be the difference in sample size and 
selection criteria. This study excluded participants under 20 years of age, while the other 
previously mentioned study included those six years and older (Mancuso et al., 2016).  The 
prevalence of DM was higher than that of LTBI. Of the total population, 8.5% were diabetic, and 
25.1% were prediabetic. These proportions corresponded to 15.5 million and 45.9 million, 
respectively. The conditional estimates of LTBI by DM status provided insight to the magnitude 
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of the relationship between the two variables in this study population. Diabetics had the highest 
prevalence of LTBI. Of the 15.5 million diabetics identified, 8.1 - 10% indicated LTBI that 
corresponded with 1.3 - 1.5 million people. For prediabetics, 6-7% of 45.9 million indicated 
LTBI, which corresponded with 2.9 - 3.4 million people.  
 
Based on the test of association for the total study population, DM measured by HbA1c was 
related to LTBI measured by TST and QFT-G. Before accounting for covariates, the odds of 
LTBI varied by DM status. Diabetics and prediabetics were significantly more likely to have 
LTBI than those with normal HbA1c. To account for confounding or effect modification, this 
relationship was tested by including relevant covariates in the model. The variables of the best fit 
model were included because they were characteristically relevant to the relationship of DM and 
LTBI. However, though the odds of LTBI was higher than diabetics and prediabetics it was not a 
significant result. Meaning that when accounting for race/ethnicity, SES, gender, BMI, age, 
country of birth, smoking status and length of time in the US the odds of LTBI was no longer 
different based on DM status.  
 
Limitations 
The limitations of this study involved the data collection process, the study design, screening 
tests and nature of disease of interest. Selection bias was inevitable with the use of survey data 
because of responder bias. Also, because of the cross-sectional study design used, it was 
impossible to infer temporality or the direction of the association between DM and LTBI. There 
was also a chance of misclassification when testing for LTBI or diagnosis of DM. There is no 
“gold standard” for LTBI detection, and the tests available are not exempt from errors (Diel, 
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Loddenkemper, Meywald-Walter, Gottschalk, & Nienhaus, 2009). Results identified by TST 
may have been confounded by factors such as the BCG vaccine or infection with nontuberculous 
mycobacterium. Typically, when TST and QFT-G have low correspondence levels, it is an 
indication of potential error and misclassification (Abdel-Samea, Ismail, Fayed, & Mohammad, 
2013). Previous studies were performed to explain the discordance in TST and QFT-G results 
(Diel et al., 2009). Something that was visible in the results for LTBI prevalence amongst 
diabetics later on in this paper. QFT-G was considered to be more accurate than TST. More 
specifically, QFT-G has higher sensitivity, specificity, positive predictive value and negative 
predictive value than TST over all (Diel et al., 2009). However, these distinctions were not 
categorical when accounting for difference characteristics of subgroups. For example, TST was 
more likely to overestimate the level of LTBI in foreign-born persons because of the chance of 
history of the BCG vaccine, while there was evidence of QFT-G producing more false-positives 
in US-born or when used in low-risk population contrary to it being more specific. Exploring the 
variability in LTBI detecting methods is popular topic of study in low-risk populations. This 
study supported previous findings and recommendations to use TST to investigate LTBI in low-
risk groups and to use QFT-G to investigate in high-risk groups to reduce inaccuracies. Also, this 
study uses a TST reaction size ≥10 mm to indicate LTBI, which was not the recommended 
measure for populations from low-incidence regions. However, it the measure used commonly in 
in previous studies (Mancuso et al., 2016). 
 
There are also limitations associated with diagnosis of diabetes using HbA1. HbA1c is primarily 
used as a marker of glycemic control in established diabetes, and there is concern that it may not 
be sensitive enough for accurate diagnosis (Cohen, Haggerty, & Herman, 2010). Researchers 
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have also discovered evidence of discordance between HbA1c and the results of other measures 
of glycemia (Cohen et al., 2010). Fasting plasma glucose (FPG) is a more favorable test for 
diagnosing diabetes because it is more cost efficient and has less of the chances of 
misclassification potential than HbA1c in initial diagnosis. HbA1c is typically more appealing 
because it is a simple, one-time test and is considered more sensitive the FPG (Bonora & 
Tuomilehto, 2011). Other factors include: the primary symptoms of clinically defined DM is 
high blood glucose and not glycation of proteins which is the secondary symptoms, HbA1c is 
likely to miss asymptomatic early cases of diabetes, those with abnormal hemoglobin traits could 
be misclassified, and finally it is not generally recommended to use the same biomarker for 
diagnosing and as for monitoring diabetes (Bonora & Tuomilehto, 2011).  
  
Public Health Implications 
Low-incidence countries like the United States have special challenges to achieve elimination of 
TB. Progression from LTBI to TB, cross-border migration and dwindling administrative or 
political commitment and visibility are a few of these challenges. Studies like ours are helpful 
because they support the relevancy of studying TB even though it is not a focus of medicine and 
public health in countries like the U.S. with the development of effective treatment tool 
significantly reduce the risk of outbreak or death. Standardization of screening, monitoring, and 
control practices are primary challenge for managing TB in populations with low- incidence. In 
high-incidence and typically low-income regions, health organizations like the WHO 
recommend that concomitant DM/TB be addressed as soon as a connection was identified. Now 
bidirectional screening practices and co-management programs are common. TB is a persistent 
problem even in both high-income countries and low-incidence countries like the U.S. 
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Bidirectional screening and co-management procedures could be considered for groups with 
confirmed risks, but the results of this study do not support the need such efforts in the U.S. 
Conclusion 
This study identified that DM and LTBI were associated in the U.S. depending on the type of 
group being studied. More studies should be performed focusing on the presence of comorbidity 
in known reservoir population like the homeless community, those in high-risk professions, and 
institutional settings like prisons. This study did not confirm that co-management practices are 
necessary in the general population. Because of the variable results found for subgroups, it did 
justify the need for more targeted studies. Performing comparative studies to review of the 
relationship of DM and TB (LTBI) in low-incidence countries in contrast to the trends in high 
incidence countries could be a direction for future studies. In this study, however, the association 
of DM and LTBI was tested and found significant for the total population, but not when 
accounting for related variables. This study found evidence of noticeable prevalence and 
distribution of potential concomitant DM/TB in groups identified with LTBI and high glycemic 
levels. Variables like SES and race/ethnicity were confirmed as a confounder and potential effect 
modifier, respectively. Further studies exploring the nature of DM and LTBI based on country of 
birth would be insightful as that was an unconfirmed potential modifier. Finally, using variables 
based on medical history or stronger screening test would help to truly identify the nature of any 
existing burden of DM/LTBI in at most risk subpopulations. Overall, the need for further 
exploration of concomitant DM/TB can be ascertained from this study.  
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Appendix:  
 
Tables:  
 
Table 1a. Descriptive statistics of study population from one-way Proc Surveyfreq analysis  
 Sample Frequency Weighted Frequency▪ 
TST 
< 10 mm 3816 173.70 
≥ 10 mm 406 9.18 
QFT-G 
Negative 3813 172.7 
Positive 409 10.1 
HbA1c 
Normal 2490 121.5 
Prediabetic 1222 45.9 
Diabetic 510 15.5 
Race/Ethnicity White 1619 123.4 
 Hispanic 868 26.5 
 Black 1100 20.3 
 Others 635 12.6 
Length of time in the US* Greater than 20 years 3592 165.9 
 5 to 20 years 477 12.9 
 Less than 5 years 153 4.1 
Gender 
Female 2137 95.4 
Male 2085 87.5 
Age 
20 to 39 years 2490 64.7 
40 to 59 years 1222 71.3 
60+ years 510 46.8 
Country of birth* 
United States 3002 152.3 
Other 1220 30.6 
Body mass index  
Normal 1328 55.5 
Overweight 1353 61.8 
Obese 1541 65.6 
Smoking status 
Never 2389 102.0 
Former 981 45.0 
Current 852 35.8 
Socioeconomic status*  
College graduate or 
above 1029 55.3 
Some college or associate 
degree 
1301 59.6 
High school graduate or 
GED equivalent 
903 37.6 
9th – 11th grade 583 19.8 
Less than 9th grade 406 10.6 
| *Missing observation combined with lowest risk group | ▪Frequency count is divided by 1 million & 
rounded to 1 decimal place | Totals: 4,222 (unweighted) and 182.9 million (weighted) |  
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Table 1b. Descriptive statistics of study population from One-way Proc Surveyfreq analysis 
 
 
(%) 
Standard 
Error of 
Percent 
95% Confidence Limits 
of Percent 
TST 
< 10 mm 94.98 0.82 93.25 96.71 
≥ 10 mm 5.02 0.82 3.29 6.75 
QFT-G 
Negative 94.45 0.51 93.38 95.53 
Positive 5.55 0.51 4.47 6.62 
HbA1c 
Normal 66.42 1.11 64.08 68.75 
Prediabetic 25.10 1.03 22.93 27.28 
Diabetic 8.48 0.57 7.27 9.69 
Race/Ethnicity 
White 67.50 4.09 58.86 76.15 
Hispanic 14.50 2.70 8.81 20.19 
Black 11.11 2.27 6.32 15.90 
Other 6.88 0.99 4.80 8.96 
Length of time in the US* 
Greater than 20 
years 
90.69 1.37 87.79 93.59 
5 to 20 years 7.08 1.03 4.90 9.26 
Less than 5 years 2.23 0.53 1.12 3.34 
Gender 
Female 52.16 0.77 50.53 53.79 
Male 47.84 0.77 46.21 49.47 
Age 
20 to 39 years 35.39 2.28 30.59 40.19 
40 to 59 years 39.01 1.42 36.02 42.00 
60+ years 25.60 1.12 23.23 27.97 
Country of birth* 
United States 83.26 2.01 79.03 87.50 
Other 16.74 2.01 12.50 20.97 
Body mass index  
Normal 30.34 1.80 26.55 34.14 
Overweight 33.77 1.31 31.01 36.53 
Obese 35.88 1.44 32.83 38.94 
Smoking status 
Never 55.79 1.44 52.76 58.82 
Former 24.61 1.33 21.80 27.41 
Current 19.60 1.05 17.38 21.82 
Socioeconomic status*  College graduate or 
above 
30.25 2.68 24.59 35.91 
Some college or 
associate degree 
32.57 1.66 29.06 36.08 
High school 
graduate or GED 
equivalent 
20.58 1.57 17.26 23.90 
9th – 11th grade 10.84 1.50 7.67 14.00 
Less than 9th grade 5.77 0.66 4.37 7.16 
| *Missing observation combined with lowest risk group |  
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Table 2. Design adjusted Chi Squareǂ Goodness of Fit Test from One-way Proc Surveyfreq analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Rao-Scott Χ2 DF Pr > ChiSq 
TST 572.71 1 <0.001 
QFT-G 1593.26 1 <0.001 
HbA1c 1072.68 2 <0.001 
Age 23.37 2 <0.001 
Body mass index 4.34 2 <0.001 
Country of birth 153.08 1 <0.001 
Gender 7.84 1 0.0051  
Race/Ethnicity 215.92 3 <0.001 
Socioeconomic status 151.40 4 <0.001 
Length of time in the US 1002.70 2 <0.001 
Smoking status 279.03 2 <0.001 
| ǂ Rao-Scott Chi-square for survey data analysis | H0: equal proportions for the levels of the 
variable | 
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Table 3a. Conditional distribution of predictors by TST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Row %  (Standard Error) 
<10 mm ≥10 mm 
Race/Ethnicity White 98.89  (0.33) 1.11  (0.33) 
Hispanic 84.55  (2.65) 15.45  (2.65) 
Black 92.29  (1.16) 7.71  (1.16) 
Other 82.92  (1.93) 17.08  (1.93) 
Length of time in the US* Greater than 20 years 96.70  (0.58) 3.30  (0.58) 
5 to 20 years 77.71  (2.59) 22.29  (5.35) 
Less than 5 years 79.88  (5.35) 20.12  (5.35) 
Country of birth* United States 98.24  (0.46) 1.76  (0.46) 
Other 78.77  (2.79) 21.23  (2.79) 
Socioeconomic status* College graduate or above 96.36  (0.70) 3.64  (0.70) 
Some college or associate degree 96.64  (0.56) 3.36  (0.56) 
High school graduate or GED 
equivalent 
95.30  (1.05) 4.70  (1.05) 
9th – 11th grade 90.98  (2.38) 9.02  (2.38) 
Less than 9th grade 84.72  (2.24) 15.28  (2.24) 
HbA1c Normal 95.89  (0.69) 4.11  (0.69) 
Pre-diabetic 93.62  (1.65) 6.38  (1.65) 
Diabetic 91.88  (1.55) 8.12  (1.55) 
Gender Female 95.36  (0.74) 4.64  (0.74) 
Male 94.57  (0.99) 5.43  (0.99) 
Ageǂ 20 to 39 years 95.35  (0.83) 4.65  (0.83) 
40 to 59 years 94.39  (1.03) 5.61  (1.03) 
60+ years 95.35  (0.91) 4.65  (0.91) 
Smoking statusǂ Never 95.04  (0.89) 4.96  (0.89) 
Former 95.17  (0.85) 4.83  (0.85) 
Current 94.55  (1.40) 5.45  (1.40) 
Body mass indexǂ Normal 94.86  (0.94) 5.14  (0.94) 
Overweight 95.17 (0.79) 4.83  (0.79) 
Obese 94.90 (1.08) 5.10  (1.08) 
| *Missing observation combined with lowest risk | ǂThese variables are not significantly 
associated with TST | 
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Table 3b. Characteristics of study population from Two-way Proc Freq analysis by TST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Weighted Frequency▪ 
<10 mm ≥10 mm 
Race/Ethnicity 
White 122.1 1.4 
Hispanic 51.6 7.8 
Black 18.8 1.6 
Other 10.4 2.2 
Length of time in the US* Greater than 20 years 160.4 5.5 
5 to 20 years 10.1 2.9 
Less than 5 years 3.3 0.8 
Country of birth* United States 145.9 2.7 
Other 24.1 6.5 
Socioeconomic status* College graduate or above 53.3 2.0 
Some college or associate 
degree 
57.6 2.0 
High school graduate or 
GED equivalent 
35.9 1.8 
9th – 11th grade 18.0 1.8 
Less than 9th grade 8.9 1.6 
HbA1c Normal 116.5 5.0 
Pre-diabetic 43.0 2.9 
Diabetic 14.3 1.3 
Gender Female 91.0 4.4 
Male 82.7 4.8 
Ageǂ 20 to 39 years 61.7 3.0 
40 to 59 years 67.3 4.0 
60+ years 44.6 2.2 
Smoking statusǂ Never 97.0 5.1 
Former 42.8 2.2 
Current 33.9 1.9 
Body mass indexǂ Normal 52.6 2.9 
Overweight 58.8 3.0 
Obese 62.3 3.3 
| *Missing observation combined with lowest risk group | ▪Frequency count are divided by 1 x 
106 & rounded to 1 decimal place |  
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Table 4a. Conditional distribution of predictors by QFT-G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Row %  (Standard Error) 
Negative Positive 
Length of time in the US* Greater than 20 years 95.59  (0.46) 4.41  (0.46) 
5 to 20 years 81.92  (2.44) 18.08  (2.44) 
Less than 5 years 88.24  (3.15) 11.76  (3.15) 
Country of birth* United States 96.84  (0.53) 3.16  (0.53) 
Other 82.57  (1.53) 17.43  (1.53) 
Race/Ethnicity White 97.17  (0.47) 2.83 (0.47) 
Hispanic 86.84  (1.27) 13.15  (1.27) 
Black 93.11  (0.99) 6.89  (0.99) 
Other 86.00  (1.18) 14.00  (1.18) 
Socioeconomic status* College graduate or above 95.80  (0.76) 4.20  (0.76) 
Some college or associate degree 96.88  (0.51) 3.12  (0.51) 
High school graduate or GED 
equivalent 
92.80  (1.34) 7.20  (1.34) 
9th – 11th grade 92.54  (1.20) 7.46  (1.20) 
Less than 9th grade 83.25  (2.24) 16.75  (2.24) 
HbA1c Normal 95.75  (0.48) 4.25  (0.48) 
Pre-diabetic 92.54  (0.93) 7.46  (0.93) 
Diabetic 89.96  (2.08) 10.04  (2.08) 
Age 20 to 39 years 96.00  (0.45) 4.00  (0.45) 
40 to 59 years 94.91  (0.99) 5.09  (0.99) 
60+ years 91.63  (0.98) 8.38  (0.98) 
Genderǂ Female 95.41  (0.60) 4.59  (0.60) 
Male 93.41  (0.59) 6.59  (0.59) 
Smoking statusǂ Never 95.26  (0.42) 4.74  (0.42) 
Former 93.70  (0.97) 6.30  (0.97) 
Current 93.13  (1.33) 6.87  (1.33) 
Body Mass Indexǂ Normal 93.62  (1.04) 6.38  (1.04) 
Overweight 94.92  (0.65) 5.08  (0.65) 
Obese 94.72  (0.60) 5.28  (0.60) 
| *Missing observation combined with lowest risk | ǂThese variables are not significantly associated 
with TST | 
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Table 4b. Characteristics of study population from Two-way Proc Freq analysis by QFT-G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted Frequency▪ 
Negative Positive 
Length of time in the US* Greater than 20 years 158.5 7.3 
5 to 20 years 10.6 2.3 
Less than 5 years 3.6 0.5 
Country of birth* United States 147.5 4.8 
Other 25.3 5.3 
Race/Ethnicity White 120.0 3.5 
Hispanic 23.0 3.5 
Black 18.9 1.4 
Other 10.8 1.8 
Socioeconomic status* College graduate or above 52.9 2.3 
Some college or associate 
degree 
57.6 1.9 
High school graduate or 
GED equivalent 
34.9 2.7 
9th – 11th grade 18.3 1.5 
Less than 9th grade 8.8 1.8 
HbA1c Normal 116.3 5.2 
Pre-diabetic 42.5 3.4 
Diabetic 14.0 1.5 
Age 20 to 39 years 62.1 2.6 
40 to 59 years 67.7 3.6 
60+ years 42.9 3.9 
Genderǂ Female 91.0 4.4 
Male 81.7 5.8 
Smoking status Never 97.2 4.8 
Former 42.2 2.8 
Current 33.4 2.5 
Body Mass Index Normal  51.9 3.5 
Overweight 58.6 3.1 
Obese 62.2 3.5 
| *Missing observation combined with lowest risk group | ▪Frequency count are divided by 1 
million  & rounded to 1 decimal place |  
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Table 5. Design adjusted Chi Squareǂ Test of Association  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 TST QFT-G 
Race/Ethnicity 
 
Χ2 527.58 209.32 
DF 3 3 
Pr > ChiSq <.0001 <0.0001 
Length of time in the US 
 
Χ2 556.48 108.36 
DF 2 2 
Pr > ChiSq <0.0001 0.0001 
Country of birth 
 
Χ2 278.58 100.82 
DF 1 1 
Pr > ChiSq <0.0001 <0.001 
Socioeconomic status Χ2 98.21 67.49 
 DF 4 4 
 Pr > ChiSq <0.0001 <0.0001 
HbA1c Χ2 9.40 24.19 
DF 2 2 
Pr > ChiSq 0.0091 <0.001 
Age Χ2 2.28 14.35 
 DF 2 2 
 Pr > ChiSq 0.3195 0.0008 
Gender Χ2 2.22 9.55 
 DF 1 1 
 Pr > ChiSq 0.1363 0.0020 
Smoking status Χ2 0.30 4.95 
 DF 2 2 
 Pr > ChiSq 0.8612 0.0842 
Body mass index Χ2 0.18 1.92 
 DF 2 2 
 Pr > ChiSq 0.9152 0.3824 
| ǂ Rao-Scott Chi-square for survey data analysis | H0: There is no association between the 
predictor and response | 
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Table 6. Unadjusted Odds Ratio from Binary Logistic Regression – TST vs. Predictors 
 TST 
Predictor OR  95% CI 
A1C  
Normal 1.00 
Pre-Diabetic 1.588 1.001 – 2.519 
Diabetic 2.060 1.268 - 3.345 
Race/Ethnicity  
White 1.00 
Hispanic 16.33 6.988 – 38.139 
Black 7.46 3.934 – 14.135 
Other 18.40 9.546 – 35.399 
Length of time in the US  
Greater than 20 years 1.00 
5 to 20 years 8.400 5.754 – 12.265 
Less than 5 years 7.380 3.542 – 15.375 
Gender  
Female 1.00 
Male 1.181 0.928 – 1.501 
Age  
20 to 39 years 1.00 
40 to 59 years 1.219  0.942 – 1.577 
60+ years 1.00 0.651 – 1.534 
Country of birth  
United States 1.00 
Other 15.020 8.044 – 28.047 
Body Mass Index  
Normal 1.00 
Overweight 0.993 0.652 – 1.513 
Obese 0.936 0.691 – 1.269 
Smoking status  
Never 1.00 
Former 0.973 0.633 – 1.495 
Current 1.105 0.688 – 1.775 
Socioeconomic status  
College graduate or above 1.00 
Some college or associate degree 0.922 0.598 - 1.422 
High school graduate or GED equivalent 1.306 0.781 – 2.184 
9th – 11th grade 2.627 1.533 – 4.501 
Less than 9th grade 4.775 2.943 - 7.755 
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Table 7. Unadjusted Odds Ratio from Binary Logistic Regression – QFT-G vs. Predictors 
 QFT-G 
Predictor OR  95% CI 
A1C  
Normal 1.00 
Pre-Diabetic 1.818 1.371 – 2.411 
Diabetic 2.518 1.427 – 4.441 
Race/Ethnicity  
White 1.00 
Hispanic 5.207 3.187 – 8.507 
Black 2.542 1.663 – 3.886 
Other 5.597 3.582 – 8.746 
Length of time in the US  
Greater than 20 years 1.00 
5 to 20 years 4.779 3.269 – 6.988 
Less than 5 years 2.887 1.296 – 6.432 
Gender  
Female 1.00 
Male 1.466 1.122 – 1.917 
Age  
20 to 39 years 1.00 
40 to 59 years 1.289 0.780 – 2.130 
60+ years 2.196 1.517 – 3.178 
Country of birth  
United States 1.00 
Other 6.447 3.941 – 10.647  
Body Mass Index  
Normal 1.00 
Overweight 0.818 0.537 – 1.245 
Obese 0.786 0.513 – 1.203 
Smoking status  
Never 1.00 
Former 1.482 0.949 – 2.316 
Current 1.351 0.943 – 1.937 
Socioeconomic status  
College graduate or above 1.00 
Some college or associate degree 0.734 0.415 – 1.300 
High school graduate or GED equivalent 1.770 0.927 – 3.377 
9th – 11th grade 1.837 1.019 – 3.312 
Less than 9th grade 4.587 2.952 – 7.128 
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Table 8. Adjusted Odds Ratio from Multiple Logistic Regression – TST 
 Model 1 Model 2 Model 3 
Predictor 
OR 
(95% CI) 
A1C  
Normal 1.00 
Pre-Diabetic 1.217  (0.711 – 2.086) 1.252  (0.716 – 2.189) 1.249  (0.713 – 2.188) 
Diabetic 1.124  (0.593 – 2.120) 1.199  (0.658 – 2.186) 1.192  (0.658 – 2.159) 
Race/Ethnicity  
White 1.00 
Hispanic 3.987  (1.595 – 9.963) 4.369  (2.049 – 9.317) 4.093  (1.665 – 10.063) 
Black 6.616  (3.827 – 11.436) 6.753  (4.056 – 11.245) 6.703  (3.904 – 11.507) 
Other 5.703  (3.079 – 10.564) 5.650  (3.098 – 10.306) 5.606  (3.002 – 10.467) 
Length of time in the 
US 
 
Greater than 20 years 1.00 
5 to 20 years 1.204  (0.885 – 1.638) -- 1.201  (0.879 – 1.641) 
Less than 5 years 1.388  (0.780 – 2.467) -- 1.381  (0.779 – 2.448) 
Gender  
Female 1.00 
Male 1.024  (0.730 – 1.437) -- 1.014   (0.726 – 1.416) 
Age  
20 to 39 years 1.00 
40 to 59 years 1.430  (1.031 – 1.983) 1.373  (1.017 – 1.854) 1.419  (1.015 – 1.984) 
60+ years 1.773  (0.983 – 3.197) 1.682  (1.022 – 2.766) 1.733  (0.965 – 3.113) 
Country of birth  
United States 1.00 
Other 7.525  (4.917 – 11.516) 8.327  (5.474 – 12.666) 7.318   (4.741 – 11.297) 
Body Mass Index  
Normal 1.00 
Overweight 0.989  (0.717 – 1.363) -- -- 
Obese 1.180  (0.742 – 1.876) -- -- 
Smoking status  
Never 1.00 
Former 1.455  (0.911 – 2.324) 1.447  (0.952 – 2.291) 1.462   (0.918 – 2.330) 
Current 1.779  (1.138 – 2.781) 1.811 (1.149 – 2.855)  
Socioeconomic status  
College graduate or 
above 
1.00 
Some college or 
associate degree 
0.891  (0.591 – 1.342) -- 0.893  (0.593 – 1.345) 
High school graduate 
or GED equivalent 
0.940  (0.607 – 1.456) -- 0.943  (0.608 – 1.463) 
9th – 11th grade 1.375  (0.765 – 2.471) -- 1.388  (0.781 – 2.465) 
Less than 9th grade 1.098  (0.477 – 2.524) -- 1.094  (0.478 – 2.505) 
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Table 9. Adjusted Odds Ratio from Multiple Logistic Regression – QFTG 
 Model 1 Model  Model 3 
Predictor 
OR 
(95% CI) 
A1C  
Normal 1.00 
Pre-Diabetic 1.281  (0.856 – 1.917) 1.260  (0.859 – 1.847) 1.251  (0.852 – 1.836) 
Diabetic 1.344  (0.623 – 2.899) 1.327  (0.660 – 2.668) 1.312  (0.650 – 2.648) 
Race/Ethnicity  
White 1.00 
Hispanic 2.060  (1.295 – 3.275) 2.047  (1.292 – 3.243) 2.024  (1.263 – 3.245) 
Black 2.538   (1.717 – 3.753) 2.540   (1.685 – 3.829) 2.541  (1.686 – 3.828) 
Other 2.482  (1.649 – 3.734) 2.582  (1.773 – 3.761) 2.601  (1.789 – 3.781) 
Length of time in the US  
Greater than 20 years 1.00 
5 to 20 years 1.165  (0.734 – 1.849) -- 1.153  (0.733 – 1.813) 
Less than 5 years 0.864  (0.474 – 1.574) -- 0.895  (0.505 – 1.586) 
Gender  
Female 1.00 
Male 1.350  (0.972 – 1.874) -- 1.327  (0.966 – 1.822) 
Age  
20 to 39 years 1.00 
40 to 59 years 1.380  (0.821 – 2.320) 1.302  (0.784 – 2.162) 1.341  (0.794 – 2.265) 
60+ years 3.110  (1.732 – 5.583) 2.936  (1.692 – 5.094) 3.075  (1.732 – 5.462) 
Country of birth  
United States 1.00 
Other 4.628  (2.497 – 8.576) 4.919   (2.871 – 8.426) 4.639  (2.587 – 8.320) 
Body Mass Index  
Normal 1.00 
Overweight 0.726  (0.447 – 1.179) -- -- 
Obese 0.830  (0.472 – 1.459) -- -- 
Smoking status  
Never 1.00 
Former 1.397  (1.203 – 3.074) 1.449  (1.069 – 2.103) 1.389  (0.946 – 2.041) 
Current 1.923  (1.203 – 3.074) 2.130  (1.375 – 3.299)) 1.969   (1.211 – 3.203) 
Socioeconomic status  
College graduate or 
above 
1.00 
Some college or 
associate degree 
0.679  (0.364 – 1.267) 0.665  (0.357 – 1.236) 0.675  (0.360 – 1.267) 
High school graduate or 
GED equivalent 
1.321 (0.672 – 2.598) 1.299  (0.667 – 2.526) 1.308  (0.662 – 2.584) 
9th – 11th grade 1.022  (0.599 – 1.743) 1.005  (0.584 – 1.731) 1.015  (0.586 – 1.759) 
Less than 9th grade 1.306  (0.855 – 1.996) 1.313  (0.848 – 2.034) 1.308  (0.851 – 2.011) 
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Figures: 
 
Figure 1. Selecting Study Population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Indeterminate results are treated as negative results for parts of this study.  
Study Population (N=4222) 
Sample population from  
NHANES 2011-2012 survey 
cycle 
(N=9756) 
Observation excluded 
based on age criteria 
(N=4196) 
Observation for participants 
20+ years of age (N=5560) 
Observations 
excluded for missing 
PPD results (N=1299) Additional obs. 
excluded for missing 
QuantiFERON 
results (N=28) * 
Additional 
Observations 
excluded for 
missing HbA1C 
results (N=11) 
ASSOCIATION BETWEEN LTBI & DM CONTROL 
 
~ 59 ~ 
 
Supporting Documents: 
 
Table A. WLRCap2015.Sas Codebook  
SAS Variable Value Label Predictor description 
Outcome indicators 
INDURATIONBIN 0 < 10 mm Tuberculin skin test result 
 1  ≥ 10 mm  
QFTG 0 Negative 
QuantiFERON Gold blood test 
result 
 1 Positive  
Exposure  
A1CCAT 1 < 5.7 (Normal) Glycohemoglobin (%) 
 2 5.7 to 6.4 (Prediabetic)  
 3 ≥ 6.5 (Diabetic)  
Covariates 
AGECAT 1 20 to 39 years  Age 
 2 40 to 59 years   
 3 60+ years   
BMICAT3 2 18.5 to 24.9 (Normal) Body Mass Index (kg/m2) 
 3 25 to 29.9 (Overweight)  
 4 ≥ 30 (Obese)  
CTRYOB 1 United States Country of Birth  
 2 Other  
GENDER 1 Female Gender 
 2 Male  
RACE4G 1 White Race with 4 categories 
 2 Hispanic  
 3 Black  
 4 Others  
SESEDUC 1 College graduate or above 
Socioeconomic Status (education 
level) 
 2 Some college or associate degree  
 3 High school graduate or GED equivalent  
 4 9 - 11th grade  
 5 Less than 9th grade  
SMOKE 1 Never Smoking Status  
 2 Former  
 3 Current  
TIME3INUS 1 Greater than 20 years Length of time in the US 
 2 5 to 20 years  
 3 Less than 5 years  
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Table B. NHANES 2011-2012 modeling variables for data analysis 
Variable Value Label Description 
RIDSTATR 2 
Both interviewed, and 
MEC examined 
Interview/Examination 
status 
SDDSRVYR 7 
NHANES 2011 – 2012 
public release 
Data release cycle 
SDMVSTRA 90 to 103 
Masked variance pseudo-
stratum 
Masked variance unit 
pseudo-stratum variable 
for variance estimation 
SDMVPSU 1 to 3 
Masked variance pseudo-
PSU 
Masked variance unit 
pseudo –PSU variable 
for variance estimation 
WTMEC2YR 0 – 222579.78343 
Full sample 2 year MEC 
exam weight 
Both interviewed, and 
MEC examined 
participants 
 
